Pharma Journalist -

Pfizer Inc. announced that the first participant has been dosed in the Phase 3 BASIS study of marstacimab (PF-06741086), an anti-tissue factor pathway inhibitor (anti-TFPI) being…
Read More...

GlaxoSmithKline plc announced that patient dosing has begun in a phase 3 clinical programme investigating the safety and efficacy of its Respiratory Syncytial Virus (RSV) candidate…
Read More...

Merck, known as MSD outside the United States and Canada, and OncoImmune, a privately-held, clinical-stage biopharmaceutical company, announced that the companies have entered into a…
Read More...

HiFiBiO Therapeutics, a multinational biotherapeutics company with unique expertise in immune modulation and single cell science, announced a partnership with Russian pharmaceutical…
Read More...

Syngene International and Deerfield Discovery and Development Corporation (3DC), the drug discovery and development subsidiary of Deerfield Management Company (Deerfield), have signed…
Read More...

Be The Match BioTherapies, an organization offering solutions for companies developing and commercializing cell and gene therapies, and Lonza announced a strategic partnership to…
Read More...

SMi Reports: SMi Group are delighted to announce that Julia Frese, Department Manager Centre of Combination Products, TÜV SÜD will be a speaker at the Pre-filled Syringes Europe…
Read More...

Novartis announced that it entered into an exclusive worldwide license and collaboration agreement with Mesoblast to develop, commercialize and manufacture remestemcel-L for the…
Read More...

RedHill Biopharma Ltd. a specialty biopharmaceutical company, today announced that it has initiated its Phase 3 study to evaluate the safety and efficacy of RHB-204 as a potential…
Read More...

AstraZeneca’s Imfinzi (durvalumab) has been approved in the US for an additional dosing option, a 1,500mg fixed dose every four weeks, in the approved indications of unresectable Stage…
Read More...